Sarcomatoid Renal Cell Carcinoma: Population-Based Study of 879 Patients
This study investigates its clinicopathologic characteristics and outcomes at a national level.03/05/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - March 5, 2019 Category: Urology & Nephrology Source Type: news
A five-gene signature predicts overall survival of patients with papillary renal cell carcinoma
This study aims to investigate the gene expression changes in papillary renal cell carcinoma(pRCC) and screen several genes and associated pathways of papillary renal cell carcinoma progression.03/05/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - March 5, 2019 Category: Urology & Nephrology Source Type: news
Brian I. Rini, MD, on Renal Cell Carcinoma: Results From the TIVO-3 Trial on Tivozanib vs Sorafenib
Brian I. Rini, MD, of the Cleveland Clinic Taussig Cancer Institute, discusses phase III findings on a comparison of tivozanib and sorafenib in patients with refractory advanced renal cell carcinoma03/04/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - March 4, 2019 Category: Urology & Nephrology Source Type: news
Brian I. Rini, MD, on Renal Cell Cancer: Risk Stratification After Resection of Localized Disease
Brian I. Rini, MD, of the Cleveland Clinic Taussig Cancer Institute, discusses current models used to estimate the risk of recurrence of kidney cancer.02/27/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 27, 2019 Category: Urology & Nephrology Source Type: news
ASCO GU 2019: When to Obtain Genetic Testing for Syndromic Renal Cell Cancer
Dr. Brian Schuch weighs in on genetic testing for kidney cancer.02/26/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 26, 2019 Category: Urology & Nephrology Source Type: news
Top Medications Used to Treat Kidney (Renal Cell Cancer)
This article discusses the top medications used to treat kidney cancer.02/25/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 25, 2019 Category: Urology & Nephrology Source Type: news
Dr. McDermott on Single-Agent Pembrolizumab in Advanced RCC
In this video, David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses the use of single-agent pembrolizumab (Keytruda) in the treatment of patients with advanced non –clear cell renal cell carcinoma (RCC).02/20/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 20, 2019 Category: Urology & Nephrology Source Type: news
New therapeutic target found for aggressive pediatric cancers with few treatment options
Researchers at the University of Texas MD Anderson Cancer Center recently discovered a new therapeutic target for malignant rhabdoid tumors (MRT). MRT is a rare pediatric cancer that commonly starts in the kidneys. Dr. Pavlos Msaouel, who was a 2017 Conquer Cancer Foundation Young Investigator Award recipient supported by the Kidney Cancer Association, was involved in this breakthrough finding.02/19/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 19, 2019 Category: Urology & Nephrology Source Type: news
ASCO GU 2019: First-line Pembrolizumab Monotherapy for Advanced Non-Clear Cell Renal Cell Carcinoma: Results from KEYNOTE-427 Cohort B
Keynote 427 Cohort B results demonstrate promising anti-tumor activity with first line pembrolizumab monotherapy in non-clear cell advanced RCC.02/19/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 19, 2019 Category: Urology & Nephrology Source Type: news
ASCO GU 2019: Analysis of Overall Survival Based on Early Tumor Shrinkage in the Phase III METEOR Study of Cabozantinib versus Everolimus in Advanced Renal Cell Carcinoma
During the Rapid Abstract Session on Renal Cell Cancer at the Annual ASCO GU 2019 meeting in San Francisco, CA, Dr. Duran presented on the analysis of overall survival (OS) based on early tumor shrinkage in the phase III METEOR study of cabozantinib (cabo) versus everolimus (eve) in advanced renal cell carcinoma (RCC).02/18/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 18, 2019 Category: Urology & Nephrology Source Type: news
ASCO GU 2019: Genetic Evolution of Metastatic Renal Cell Cancer
At ASCO GU in San Francisco, Dr. Samra Turajlic discussed the evolution of metastatic renal cell carcinoma.02/18/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 18, 2019 Category: Urology & Nephrology Source Type: news
Merck Highlights Breadth of Immuno-Oncology Research Program in Genitourinary Cancers at ASCO GU
Merck announced yesterday that new combination and monotherapy data from the company ’s broad immuno-oncology research program in genitourinary cancers – renal, prostate and bladder − will be presented at the 2019 Genitourinary Cancers Symposium (ASCO GU) in San Francisco from February 14-16.02/12/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 12, 2019 Category: Urology & Nephrology Source Type: news
Aerobics, Strength Exercises Improve Quality of Life in Kidney Cancer Survivors
Meeting combined exercise guidelines – including both aerobics and strength training – improved quality of life in #KidneyCancer survivors; however, few individuals reported they follow such guidelines, according to study findings published in Psycho-Oncology.02/12/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 12, 2019 Category: Urology & Nephrology Source Type: news
